Open Data Collaboration Shows AI Can Accurately Diagnose Prostate Cancer
A large study led by the Karolinska Institute in Sweden shows that artificial intelligence can be used to accurately diagnose and grade prostate cancer in a way that is generalizable across different populations.
Precision Medicine Platform Trial Aims to Develop Treatments for Rare Cancers
Cancer Research UK’s Centre for Drug Development will sponsor and manage the trial and Roche will provide the first five targeted therapies for evaluation.
Sema4 to Acquire GeneDx for Approximately $623 Million
Central to the deal was GeneDx’s rare disease diagnosis and clinical exome sequencing capabilities along with data from more than 300,000 exomes and 2.1 million annotated patient phenotypes.
Link Between Epstein-Barr Virus and Multiple Sclerosis Strengthened by New Study
Large-scale study strengthens link between Epstein-Barr Virus (EBV) infection and multiple sclerosis (MS). Prior EBV infection raises risk of MS 32-fold.
Specificity Of Base Editing Improved by Virus-Like Particle Delivery System
New findings suggest engineered DNA-free virus-like particles are an attractive alternative to other delivery strategies for the in vivo or ex vivo delivery of base editors, nucleases, and other proteins of therapeutic interest.
NCCN Publishes Guidance on COVID-19 Vaccination, Antibody Treatments for Cancer Patients
Of note in the recently released updated guidance, was information on the use of a human monoclonal antibody treatment regimen as a preventive measure against contracting COVID-19.
ASO Cocktail Corrects Severe Cystic Fibrosis Mutation
A combination of splice-switching antisense oligonucleotides could work against a common CFTR mutation that causes a severe form of cystic fibrosis, according to new research.
Blood Test Improves Selection for Lung Cancer Screening in Long-Term Smokers
The four-marker protein panel (4MP) includes four proteins—the precursor form of surfactant protein B, cancer antigen 125, carcinoembryonic antigen, and cytokeratin-19 fragment—that have previously shown potential to identify people at risk of developing lung cancer.
Exact Sciences Acquires PreventionGenetics and Licenses OncXerna Lab Services
Cancer diagnostics company Exact Sciences has acquired PreventionGenetics and entered an exclusive license agreement for OncXerna’s Xerna TME Panel Lab to support its entrance into the field of hereditary cancer testing and cancer prognosis prediction.
Early-Stage Research Uncovers Female Specific Biomarker for Depression
Through research done mostly in a mouse model, Canadian scientists have identified a biomarker, soluble E-selectin, that could be used to test whether women, but not men, have neurovascular signs of depression.
